Meeting
2021 Genitourinary Cancers Symposium
Salvage nivolumab plus ipilimumab after prior PD-1/PD-L1 inhibitor treatment in metastatic renal cell carcinoma: A meta-analysis.
Authors
Ming Yin
The Ohio State University, Division of Medical Oncology, Columbus, OH
Ming Yin , Sherry Mori-Vogt , Megan Hinkley , Anish B Parikh , Yuanquan Yang , Katharine Collier , Abdul Miah , Mingjia Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 305)
DOI
10.1200/JCO.2021.39.6_suppl.305
Abstract #
305
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2016 ASCO Annual Meeting
Modeling the cost of immune checkpoint inhibitor-related toxicities.
First Author: Neil Thomas Mason
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah